These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17878399)

  • 1. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.
    Mielke S; Nunes R; Rezvani K; Fellowes VS; Venne A; Solomon SR; Fan Y; Gostick E; Price DA; Scotto C; Read EJ; Barrett AJ
    Blood; 2008 Apr; 111(8):4392-402. PubMed ID: 17878399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome.
    McIver ZA; Melenhorst JJ; Grim A; Naguib N; Weber G; Fellowes V; Khuu H; Stroncek DS; Leitman SF; Battiwalla M; Barrett AJ
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1846-54. PubMed ID: 21684345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses.
    Amrolia PJ; Muccioli-Casadei G; Yvon E; Huls H; Sili U; Wieder ED; Bollard C; Michalek J; Ghetie V; Heslop HE; Molldrem JJ; Rooney CM; Schlinder J; Vitetta E; Brenner MK
    Blood; 2003 Sep; 102(6):2292-9. PubMed ID: 12763937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use.
    Albon SJ; Mancao C; Gilmour K; White G; Ricciardelli I; Brewin J; Lugthart G; Wallace R; Amrolia PJ
    Cytotherapy; 2013 Jan; 15(1):109-21. PubMed ID: 23260091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro methotrexate as a practical approach to selective allodepletion.
    Sathe A; Ortega SB; Mundy DI; Collins RH; Karandikar NJ
    Biol Blood Marrow Transplant; 2007 Jun; 13(6):644-54. PubMed ID: 17531774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings.
    Davies JK; Koh MB; Lowdell MW
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
    Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
    Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis.
    Koh MB; Prentice HG; Lowdell MW
    Bone Marrow Transplant; 1999 May; 23(10):1071-9. PubMed ID: 10373075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
    Hartwig UF; Nonn M; Khan S; Link I; Huber C; Herr W
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):99-109. PubMed ID: 18158966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.
    Perruccio K; Topini F; Tosti A; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
    Blood Cells Mol Dis; 2008; 40(1):76-83. PubMed ID: 17977031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells.
    Guimond M; Balassy A; Barrette M; Brochu S; Perreault C; Roy DC
    Blood; 2002 Jul; 100(2):375-82. PubMed ID: 12091325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective depletion of alloreactive donor T cells leads to elimination of graft-versus-host reactivity and stimulates graft-versus-leukaemia/myeloma effect.
    Matějková E; Foltánková V; Burešová I
    Folia Biol (Praha); 2013; 59(4):146-53. PubMed ID: 24093772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
    Wehler TC; Nonn M; Brandt B; Britten CM; Gröne M; Todorova M; Link I; Khan SA; Meyer RG; Huber C; Hartwig UF; Herr W
    Blood; 2007 Jan; 109(1):365-73. PubMed ID: 16931626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical-scale selective depletion of alloreactive T cells using an anti-CD25 immunotoxin.
    Michálek J; Collins RH; Vitetta ES
    Neoplasma; 2003; 50(4):296-9. PubMed ID: 12937844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation.
    Bastien JP; Roy J; Roy DC
    Semin Oncol; 2012 Dec; 39(6):674-82. PubMed ID: 23206844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectors.
    Ge X; Brown J; Sykes M; Boussiotis VA
    Biol Blood Marrow Transplant; 2008 May; 14(5):518-30. PubMed ID: 18410894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies.
    Mielke S; McIver ZA; Shenoy A; Fellowes V; Khuu H; Stroncek DF; Leitman SF; Childs R; Battiwalla M; Koklanaris E; Haggerty J; Savani BN; Rezvani K; Barrett AJ
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1855-61. PubMed ID: 21684344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy.
    Samarasinghe S; Mancao C; Pule M; Nawroly N; Karlsson H; Brewin J; Openshaw P; Gaspar HB; Veys P; Amrolia PJ
    Blood; 2010 Jan; 115(2):396-407. PubMed ID: 19890093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation.
    Solomon SR; Tran T; Carter CS; Donnelly S; Hensel N; Schindler J; Bahceci E; Ghetie V; Michálek J; Mavroudis D; Read EJ; Vitetta ES; Barrett AJ
    Cytotherapy; 2002; 4(5):395-406. PubMed ID: 12473206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Photodepletion differentially affects CD4+ Tregs versus CD4+ effector T cells from patients with chronic graft-versus-host disease.
    Bastien JP; Krosl G; Therien C; Rashkovan M; Scotto C; Cohen S; Allan DS; Hogge D; Egeler RM; Perreault C; Roy DC
    Blood; 2010 Dec; 116(23):4859-69. PubMed ID: 20798236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.